Click here for Canada websiteNews release 2020
Search results:
Results for ""
2022
News release 2022
Covis Pharma Group Announces Two Executive Management Team Appointments
Press ReleaseCovis Pharma Group Announces Two Executive Management Team Appointments – Michelle Lock Joins Covis Pharma as Chief Operating Officer. – Also Announces Executive Leadership Transition with the Appointment of Sandy Loreaux as President, U.S. Business.Zug,...
Products
ProductsRespiratoryProduct WebsiteUS Prescribing informationProvider Sample Request FormUS Prescribing informationProduct WebsiteUS Prescribing informationProvider Sample Request FormAllergyUS Prescribing informationUS Prescribing informationOncologyProduct...
About
About CovisFounded in 2011, Covis Pharma is a private equity backed global specialty pharmaceutical company that markets therapeutic solutions in 50+ countries, for patients with life-threatening conditions and chronic illnesses. Our purpose is to turn untapped...
Legal Statement
Legal StatementLast Updated: February 11, 2020 TERMS OF USE These terms, conditions and notices contained herein (collectively, “Terms”) apply to all websites ( “Site” or “Sites”) operated by Covis Pharma B.V or its affiliates, subsidiaries, assigns, successors,...
Privacy Policy
Covis Pharma – Website Privacy NoticeLast updated: 22 February 2023 Covis Group S.à.r.l. along with its group companies, (together referred to as "Covis Pharma", "we" or "us") respect your right to privacy. This Privacy Notice explains who we are, how we collect,...
Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca
Press ReleaseCovis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca - Enters into on an Exclusive Promotion and Distribution Agreement with Novartis for Distribution Rights to Seebri® Breezhaler® and Ultibro® Breezhaler® in...
Covis Pharma Group Announces Two Executive Management Team Appointments
Press ReleaseCovis Pharma Group Announces Two Executive Management Team Appointments -Appointment of Raghav Chari as Chief Innovation Officer to lead product portfolio lifecycle management. -Appointment of Nicolas Verbeke as Senior Vice President, Europe &...
Covis Significantly Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZeneca
Press ReleaseCovis Significantly Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZenecaZUG, SWITZERLAND, November 1, 2021 – Covis Pharma Group (“Covis”), a global specialty pharmaceutical company that markets therapeutic...
New data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patients
Press ReleaseNew data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patientsZug, Switzerland, October 4, 2021 – Covis Pharma GmbH (“Covis”) and Norgine B.V. (“Norgine”) today announced data...
News
News
Covis Pharma Announces FDA’s Decision to Grant Public Hearing for Only FDA-Approved Treatment to Reduce Preterm Birth in Indicated Patients
Press ReleaseCovis Pharma Announces FDA’s Decision to Grant Public Hearing for Only FDA-Approved Treatment to Reduce Preterm Birth in Indicated PatientsZug, Switzerland, August 19, 2021 - Covis Group S.à r.l. (“Covis”) announced today that the U.S. Food and Drug...
Timeline
Historic Milestones
Careers
CareersCareers at Covis PharmaFounded in 2011, Covis Pharma is a private equity backed global specialty pharmaceutical company that markets therapeutic solutions in 50+ countries, for patients with life-threatening conditions and chronic illnesses. Our purpose is to...
Compliance
California Compliance StatementStatement regarding compliance with California Health & Safety Code §119402Pursuant to California Health & Safety Code, Sections 119400 - 119402, (“California Compliance Law”), which requires the adoption of a comprehensive...
Covis Pharma Canada Ltd. Privacy Policy
Privacy PolicyCOVIS PHARMA CANADA LTD. OUR COMMITMENT TO PRIVACY Covis Pharma Canada Ltd. (together with its subsidiaries “we,” “us” or “Covis”) is committed to maintaining the security, confidentiality and privacy of your personal information. This is our Privacy...
Homepage
Our patients are our paramount concern. We market therapeutic solutions for patients with life-threatening conditions and chronic illnesses.Covis is led by one of the strongest and longest-tenured senior management teams committed to delivering therapeutic solutions...
COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide)
Press ReleaseCOVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide)Zug, Switzerland, April 15, 2021 - Covis Pharma Group (the “Company”), a global specialty...
EPPPIC Study Reaffirms 17-OHPC for Reducing Early Preterm Birth in High-Risk, Singleton Pregnancies
Press ReleaseEPPPIC Study Reaffirms 17-OHPC for Reducing Early Preterm Birth in High-Risk, Singleton PregnanciesLUXEMBOURG and ZUG, Switzerland – March 26, 2021 – Covis Group S.à r.l. (“Covis”) announced today that the updated results of EPPPIC (Evaluating...
AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection)
Press ReleaseAMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection)WALTHAM, Mass., December 14, 2020 – AMAG...